All In Biotech

Drug Trial Radar · NCT07824323

Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome

EARLY-BIRD ACS Trial: Early Aggressive Lipid-Lowering Regimen With Bempedoic Acid Initiated for Reducing Dyslipidemia in Patients With Acute Coronary Syndrome

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Aug 26, 2026

Primary completion

Mar 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Taipei Medical University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized clinical trial will evaluate whether starting bempedoic acid in addition to high-intensity statin therapy and ezetimibe within 72 hours after percutaneous coronary intervention improves low-density lipoprotein cholesterol (LDL-C) control in adults with acute coronary syndrome. Participants will receive either triple therapy with a high-intensity statin, ezetimibe, and bempedoic acid or standard dual therapy with a high-intensity statin and ezetimibe for 12 weeks. The primary outcome is the proportion of participants with LDL-C below 55 mg/dL at Week 12. Changes in lipid and inflammatory markers, medication adherence, and treatment-emergent adverse events will also be assessed.

Conditions

  • Acute Coronary Syndromes
  • Dyslipidemia

Interventions

  • bempedoic acidDrug

    Bempedoic acid 180 mg tablet taken orally once daily for 12 weeks.

  • EzetimibeDrug

    Ezetimibe 10 mg tablet taken orally once daily for 12 weeks.

  • High-Intensity Statin TherapyDrug

    Atorvastatin 40 mg orally once daily or rosuvastatin 20 mg orally once daily for 12 weeks, selected according to clinical judgment and routine practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants Achieving LDL-C Below 55 mg/dL at Week 12Time frame: Week 12 (visit window: +/- 2 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taipei Medical University Hospital

    Taipei, Taipei City, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.